Certain of the representations of Taro are qualified by materiality or a material adverse effect
standard. For purposes of the merger agreement, material adverse effect means an effect, change, event or circumstance (each, an Effect) that, considered together with all other Effects, has a material adverse effect on:
(a) the business, assets, liabilities, condition (financial or otherwise), operations or results of operations of Taro and its subsidiaries taken as a whole; or (b) the ability of Taro to consummate the Transactions or to perform any of
its covenants or obligations under the merger agreement; provided, however, that certain matters are not taken into account in determining whether a material adverse effect has occurred: (i) changes in the economy or financial markets
(including credit markets) in general, (ii) changes in the economic, business, financial or regulatory environment generally affecting any of the industries in which Taro and its subsidiaries operate, (iii) changes in law or applicable
accounting regulations or principles or interpretations thereof, (iv) changes that arise out of the existence or announcement of the merger agreement or out of actions required by the Transactions, (v) acts of war, armed hostilities or
terrorism or any escalation or worsening of any acts of war, armed hostilities or terrorism (other than such acts of war, armed hostilities or terrorism, or escalation or worsening thereof, that cause any damage or destruction to, or render
physically unusable, any facility or property of Taro or any of its subsidiaries or otherwise disrupt in any material manner the business or operations of Taro or any of its material subsidiaries), (vi) any failure, in and of itself, of Taro to
achieve any projections, forecasts, estimates, plans, predictions, performance metrics or operating statistics (provided that the cause or basis for Taros failure to meet such projections, forecasts, estimates, plans, predictions, performance
metrics or operating statistics shall not be excluded from the determination of whether a material adverse effect has occurred) and (vii) any litigation arising from allegations of a breach of fiduciary duty or other violation of applicable law
relating to the Transactions, or the approval and adoption thereof; provided, however, that with respect to clauses (i), (ii) and (iii), solely to the extent that the impact of such change or effect is not disproportionately adverse in any material
respects to Taro and its subsidiaries taken as a whole compared to other companies in the same industry.
合併協議包含Sun Pharma實體的聲明和保證，其中涉及：Sun Pharma實體的組織和資格; Sun Pharma實體簽署、交付和執行合併協議、合併和合並協議預期的其他交易的權限;合併協議的約束性質;無需股東投票;充足的融資;披露;分享所有權
合併協議中的陳述和保證不容易概括，並且可能受到雙方在談判合併協議條款時
同意的重要限制和條件的約束。此外，某些陳述和保證可能受到與通常適用於向股東公開
披露的合同重要性標準不同的合同重要性標準的約束，或者可能被用於在各方之間分配風險而不是確定事實。請您仔細閲讀合併協議中標題為
公司的聲明和聲明以及Sun Pharma、Alkaloida、TDC、SPH和Merger Sub的聲明和聲明的章節。合併協議中包含的各方陳述和保證在合併完成時失效。
代理聲明;附表13 E-3;股東
會議
Taro同意準備本委託書，並在特別委員會合理批准委託書內容的前提下，儘快將本委託書郵寄給Taro的股東（前提是，如果適用，該日期應在SEC或其工作人員通知其對附表13 E-3（定義見下文）沒有進一步評論的日期之後）。Taro還同意使本委託書符合適用於其的法律要求，為Sun Pharma提供合理的機會來審查和評論本委託書的草稿，並立即將委託書提交給SEC。雙方同意共同準備與交易有關的附表13 E-3（以下簡稱附表13 E-3），並在附表13 E-3內容獲得特別委員會合理批准的情況下，立即將附表13 E-3提交給美國證券交易委員會。Taro同意在收到SEC就附表13 E-3提出的任何意見以及SEC就附表13 E-3提出的任何修訂請求或其他信息時，儘快通知Sun Pharma，並同意向Sun提供
51
